email article 
print
New Report on Pfizer Inc.
September 02, 2008 --
LONDON, UNITED KINGDOM -- (Marketwire) -- 09/02/08 -- Reportlinker.com announces that a new market research report related to the Healthcare industry is available in its catalogue.
Pfizer Inc.: PharmaVitae Profile
http://www.reportlinker.com/p092394/Pfizer-Inc-PharmaVitae-Profile.html
Introduction
This analysis examines the historical and forecast performance for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Pfizer's performance against key rivals in the ethical pharmaceutical sector
- Assess how Pfizer's M&A driven growth strategy will continue to impact the company's commercial performance out to 2013
- Analyze the impact of patent expiry for Pfizer's flagship product Lipitor, which accounted for c.29% of the company's prescription drug sales in 2007
CHAPTER 1 ABOUT THIS PROFILE 2 Executive summary 2 Quarterly news update 2 Company introduction 2 Company sales 2 Company financials 2 Key products and competitors 3 Data sourcing 3 Sales data 3 Analyst consensus 3 CHAPTER 2 EXECUTIVE SUMMARY 4 Key findings 4 Prescription pharmaceutical sales performance, 2001-13 6 Financial performance, 2001-13 7 Pfizer: PharmaVitae forecasts at a glance 8 Strategic insight 9 Introduction 9 Pfizer pre-2001 - the Warner-Lambert acquisition 9 Uptake of Lipitor - the blockbuster redefined 10 Pfizer returns to the M&A trail - the Pharmacia acquisition 11 Pfizer seeks to replicate Lipitor success with Cox-2 franchise 12 Lipitor - a double edged sword? 13 Failure of Torcetrapib - No second chance for Lipitor 14 What next for Pfizer? 15 Internal revenue growth to prove insufficient 15 Pfizer leads peer set into cost cutting territory 16 In-licensing to remain a key opportunity 18 Conclusions 19 SWOT analysis 21 Strengths 21 Weaknesses 22 Opportunities 23 Threats 24 CHAPTER 3 QUARTERLY NEWS UPDATE 29 Product developments 29 Deals and alliances 30 Product deals 30 Technology deals 33 M&A activity 35 Company announcements 36 Future product milestones 44 CHAPTER 4 COMPANY INTRODUCTION 47 Key findings 47 Background 48 Key corporate developments 48 M&A history & strategy 49 Warner-Lambert 49 Pharmacia 50 CHAPTER 5 COMPANY SALES 52 Key findings 52 Prescription pharmaceutical sales and growth rate analysis, 2001-13 53 Product analysis 56 Product analysis, 2001-07 57 Product analysis, 2007-13 61 Therapy area analysis 64 Therapy area analysis, 2001-07 65 Therapy area analysis, 2007-13 67 Therapy area focus, 2001-13 68 Geographic analysis 70 Geographic analysis, 2001-07 71 Geographic analysis, 2007-13 73 Geographic focus, 2001-13 75 Launch/core/expiry analysis 76 Explanation of launch/core/expiry analysis 76 Launch analysis, 2007-13 77 Core analysis, 2007-13 79 Expiry analysis, 2007-13 81 Launch/core/expiry configuration, 2007-13 83 Molecule type analysis 84 Molecule type analysis, 2001-07 85 Molecule type analysis, 2007-13 86 Externalization analysis 89 Externalization analysis, 2001-07 90 Externalization analysis, 2007-13 92 CHAPTER 6 COMPANY FINANCIALS 95 Key findings 95 Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 96 Financial statements, 2001-07 98 Profit and loss account, 2001-07 98 Balance sheet, 2001-07 101 Operating costs and profit analysis 103 Operating costs and profit analysis, 2001-07 104 Operating cost ratio and profit margin analysis, 2001-07 106 Operating cost ratio and profit margin analysis, 2007-13 108 Operating costs and profit analysis, 2007-13 110 Return on capital employed analysis 113 Capital employed analysis, 2001-07 114 Return on capital employed (RoCE) analysis, 2001-07 116 Market capitalization analysis 118 Market capitalization analysis, 2001-07 118 Total shareholder returns analysis, 2001-07 120 CHAPTER 7 KEY PRODUCTS AND COMPETITORS 122 Key findings 122 Overview 123 Cardiovascular 124 Lipitor 124 Overview 125 Sales forecast 126 Norvasc 129 Overview 130 Sales forecast 131 Central Nervous System (CNS) 132 Lyrica 132 Overview 133 Sales forecast 134 Chantix/Champix 136 Overview 137 Sales forecast 138 Zoloft 140 Overview 141 Sales forecast 142 Oncology 144 Sutent 144 Overview 145 Sales forecast 146 Immunology & Inflammation 150 Celebrex 150 Overview 151 Sales forecast 152 Urology & gender specific health 154 Viagra 154 Overview 155 Sales forecast 156 Detrol/Detrol LA 157 Overview 158 Sales forecast 159 Infectious diseases 161 Vfend 161 Overview 162 Sales forecast 163 Zyvox 165 Overview 166 Sales forecast 167 Selzentry 169 Overview 170 Sales forecast 171 Respiratory 173 Zyrtec/Zyrtec D 173 Overview 174 Sales forecast 175 CHAPTER 8 APPENDIX 177 R&D pipeline 177 Abbreviations 180 Exchange rates 181 List of Tables Table 1: Pfizer - PharmaVitae forecasts at a glance 8 Table 2: Pfizer key product developments, Q1 and Q2 2008 29 Table 3: Pfizer product deals and alliances, Q1 and Q2 2008 30 Table 4: Pfizer technology deals and alliances, Q1 and Q2 2008 33 Table 5: Pfizer M&A activity, Q1 and Q2 2008 35 Table 6: Pfizer company announcements, Q1 and Q2 2008 36 Table 7: Pfizer future product milestones, 2008-10 44 Table 8: Pfizer product portfolio overview ($m), 2001-07 57 Table 9: Pfizer product portfolio overview ($m), 2007-13 61 Table 10: Pfizer product portfolio overview ($m), 2001-07 65 Table 11: Pfizer product portfolio overview ($m), 2007-13 67 Table 12: Pfizer portfolio overview by geographic region ($m), 2001-07 71 Table 13: Pfizer portfolio overview by geographic region ($m), 2007-13 73 Table 14: Pfizer launch portfolio overview ($m), 2007-13 77 Table 15: Pfizer core portfolio overview ($m), 2007-13 79 Table 16: Pfizer expiry portfolio overview ($m), 2007-13 81 Table 17: Pfizer portfolio overview by molecule type ($m), 2001-07 85 Table 18: Pfizer product portfolio overview by molecule type ($m), 2007-13 86 Table 19: Pfizer product portfolio overview by source ($m), 2001-07 90 Table 20: Pfizer product portfolio overview by source ($m), 2007-13 92 Table 21: Total Pfizer sales by business unit ($m), 2001-07 96 Table 22: Pfizer profit and loss account ($m), 2001-07 98 Table 23: Pfizer balance sheet ($m), 2001-07 101 Table 24: Pfizer operating revenue/cost analysis ($m), 2001-07 104 Table 25: Pfizer operating cost ratio analysis (% of total revenues), 2001-07 106 Table 26: Pfizer operating cost ratio analysis (% of total revenues), 2007-13 108 Table 27: Pfizer operating revenue/cost analysis ($m), 2007-13 110 Table 28: Calculation of average 'other operating (expenditure)/income' for Pfizer operating revenue/cost analysis ($m), 2007-13 111 Table 29: Pfizer capital employed ($m), 2001-07 114 Table 30: Pfizer EBIT return on capital employed ($m), 2001-07 116 Table 31: Pfizer EBIT pre-tax return/Capital employed driver analysis (%), 2001-07 117 Table 32: Pfizer market capitalization ($ billion), 2001-07 118 Table 33: Pfizer total shareholder returns (annual %), 2001-07 120 Table 34: Key products overview 123 Table 35: Lipitor: overview 125 Table 36: Lipitor: sales forecast ($m), 2007-13 126 Table 37: Norvasc: overview 130 Table 38: Norvasc: sales forecast ($m), 2007-13 131 Table 39: Lyrica: overview 133 Table 40: Lyrica: sales forecast ($m), 2007-13 134 Table 41: Chantix/Champix: overview 137 Table 42: Chantix/Champix: sales forecast ($m), 2007-13 138 Table 43: Zoloft: overview 141 Table 44: Zoloft: sales forecast ($m), 2007-13 142 Table 45: Sutent: overview 145 Table 46: Sutent: sales forecast ($m), 2007-13 146 Table 47: Celebrex: overview 151 Table 48: Celebrex: sales forecast ($m), 2007-13 152 Table 49: Viagra: overview 155 Table 50: Viagra: sales forecast ($m), 2007-13 156 Table 51: Detrol/Detrol LA: overview 158 Table 52: Detrol/Detrol LA: sales forecast ($m), 2007-13 159 Table 53: Vfend: overview 162 Table 54: Vfend: sales forecast ($m), 2007-13 163 Table 55: Zyvox: overview 166 Table 56: Zyvox: sales forecast ($m), 2007-13 167 Table 57: Selzentry: overview 170 Table 58: Selzentry: sales forecast ($m), 2007-13 171 Table 59: Zyrtec/Zyrtec D: overview 174 Table 60: Zyrtec/Zyrtec D: sales forecast ($m), 2007-13 175 Table 61: Pfizer's R&D pipeline (Phase I-registration) 177 Table 62: Exchange rates, 2007 181 List of Figures Figure 1: Pfizer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 6 Figure 2: Pfizer's financial performance ($m), 2001-13 7 Figure 3: Pfizer prescription pharmaceutical sales by M&A activity ($m), 2001-13 11 Figure 4: Lipitor sales as a percentage of Pfizer prescription pharmaceutical sales ($m), 2001-13 13 Figure 5: Reduction in SG&A costs to drive only temporary growth in operating profit 18 Figure 6: Pfizer SWOT analysis 21 Figure 7: Pfizer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 54 Figure 8: Pfizer key sales growth driver & resistors ($m), 2001-07 58 Figure 9: Pfizer key sales growth drivers & resistors ($m), 2007-13 62 Figure 10: Pfizer prescription pharmaceutical sales by therapy area ($m), 2001-13 64 Figure 11: Pfizer prescription pharma sales by therapy area (% of total), 2001-13 68 Figure 12: Pfizer prescription pharmaceutical sales by geographic region ($m), 2001-13 70 Figure 13: Pfizer growth drivers and resistors by geographic region ($m), 2001-07 71 Figure 14: Pfizer drivers and resistors by geographic region ($m), 2007-13 73 Figure 15: Pfizer prescription pharmaceutical sales by geographic regio n (% of total), 2001-13 75 Figure 16: Pfizer launch/core/expiry configuration ($m), 2007-13 83 Figure 17: Pfizer prescription pharmaceutical sales by molecule type ($m), 2001-13 84 Figure 18: Pfizer growth drivers and resistors by molecule type ($m), 2007-13 87 Figure 19: Pfizer prescription pharmaceutical sales by source ($m), 2001-13 89 Figure 20: Pfizer growth drivers and resistors by source ($m), 2001-07 90 Figure 21: Pfizer growth drivers and resistors by source ($m), 2007-13 93 Figure 22: Pfizer operating revenue/cost analysis ($m), 2001-13 103 Figure 23: Pfizer operating cost ratio analysis (% of total revenues), 2001-13 109 Figure 24: Pfizer return on capital employed, EBIT margin and capital turnover, 2001-07 113 Figure 25: Return on capital employed formula 117 Figure 26: Pfizer market capitalization ($ billion), 2001-07 119 Figure 27: Pfizer total shareholder returns vs. S&P 500 ($m), 2001-07 121
To order this report:
Pfizer Inc.: PharmaVitae Profile
http://www.reportlinker.com/p092394/Pfizer-Inc-PharmaVitae-Profile.html
More market research reports here!
Contacts:
Reportlinker.com
Nicolas
(718) 887-3024
Email: nbo@reportlinker.com
With 1 Reviews.
With 6 Reviews.
